NVIDIA Clara Parabricks Pipelines Files IPO Prospectus, Revolutionizing Genomic Secondary Analysis with GPU-Accelerated Speed and Precision

Whether applied to FASTQ files generated by sequencers or variant call format (VCF) files, NVIDIA Clara Parabricks Pipelines can accelerate secondary analysis by 30 to 60 times. Furthermore, Clara Parabricks Pipelines deliver results comparable to those of commonly used secondary analysis tools such as GATK4 and DeepVariant, while significantly increasing throughput.

Clara Parabricks Pipelines leverages graphics processing units (GPUs) to accelerate secondary analysis. Running current analyses on a machine equipped with 32 vCPUs would require nearly 30 hours of computation time. In contrast, Clara Parabricks Pipelines accelerates these computations by employing the same algorithms used by GATK4, completing the analysis within 20 minutes using eight NVIDIA A100 GPUs. Clara Parabricks Pipelines supports all GATK4 best practices and is fully configurable, allowing users to select specific steps and pipeline versions for execution.

By leveraging GPU-accelerated computing, Clara Parabricks Pipelines can deliver throughput on a single GPU server equivalent to that of nearly 40 to 50 CPU servers, thereby reducing IT management overhead and operational costs (including power and cooling). Whether for the analysis or re-analysis of NGS data, Clara Parabricks Pipelines is rapidly emerging as a preferred solution, significantly enhancing the efficiency of existing workflows while supporting user-driven customization. For cloud users, where computational costs are proportional to execution time, Parabricks can reduce runtime to 1/30th to 1/60th of that required by CPU-only solutions, lowering total computational costs by up to 50%.

After alignment, sorting, duplicate marking, and Base Quality Score Recalibration (BQSR), this solution produces BAM files identical to the benchmark. As the benchmark variant calling software is non-deterministic, its output may vary slightly depending on specific parameters. In this step, the results generated by this software exhibit a 99.999% concordance with the benchmark execution results.

Learn more about NVIDIA healthcare and life sciences solutions. Click herePro TopicPage.